Single-nucleotide polymorphisms of matrix metalloproteinases and their inhibitors in gastrointestinal cancer

Table 3 Polymorphisms of matrix metalloproteinases in hepatocellular carcinoma

Gene	SNP	Reference	Cancer type	Ethnicity	Case/control	Outcome parameter	Results	Parameter OR	OR	95% CI	P value
MMP-1	-1607 1G/2G	Matsumura[65]	Gastric	Japanese	215/166	Cancer risk	No difference in cancer risk
						Clinicopathol. par.	No correlation with any clinicopath. par.
		Jin[42]	GCA	Chinese	183/350	Cancer risk	No difference in cancer risk
						LN metastases	No difference in LN metastases
MMP-2	-1306 C/T	Zhang[53]	Gastric	Chinese	228/774	Cancer risk	Increased cancer risk in CC	CC vs CT/TT	1.67	1.17-2.38
		Wu[55]	Gastric	Taiwanese	240/283	Cancer risk	No difference in cancer risk
						LN metastases	Increased risk of lymphatic invasion in CC	CC vs CT+TT	2.77	1.27-6.04	0.01
						Venous invasion	Increased risk of venous invasion in CC	CC vs CT+TT	2.93	1.27-6.78	0.012
						Survival	No difference in survival
		Kubben[14]	Gastric	Caucasian	79/169	Cancer risk	No difference in cancer risk
						Tumor-related survival	No difference in tumor-related survival
		Alakus[56]	Gastric	Caucasian	135/58	Cancer risk	No difference in cancer risk
						MMP-2 protein expression	No correlation with protein expression
						Overall survival	No difference in overall survival
		Li[39]	GCA	Chinese	257/624	Cancer risk	No difference in cancer risk
		Miao[54]	GCA	Chinese	356/789	Cancer risk	Increased cancer risk in CC	CC vs CT+TT	3.36	2.34-4.97
						Distant metastases	No difference in metastases
MMP-2	-735 C/T	Li[39]	GCA	Chinese	257/624	Cancer risk	Trend towards increased cancer risk in CC	CC vs CT+TT	1.36	0.99-1.87	0.06
						Cancer risk in non-smoker	Increased cancer risk in CC in non-smoker	CC vs CT+TT	1.7	1.07-2.68	0.02
MMP-3	-1171 6A/5A	Zhang[44]	GCA	Chinese	183/350	Cancer risk	No difference in cancer risk
						Cancer risk in smoker	No difference in cancer risk in smoker
						LN metastases	No difference in LN metastases
						Infiltration depth	No difference in infiltration depth
MMP-8	-799 C/T	Kubben[14]	Gastric	Caucasian	79/169	Cancer risk	No difference in cancer risk
						Tumor-related survival	No difference in tumor-related survival
MMP-7	-181 A/G	Sugimoto[63]	Gastric	Japanese	160/434	Cancer risk	Increased cancer risk in G-allele carriers	AG+GG vs AA	2.32	1.24-4.35	0.009
						Cancer stage	Increased cancer stage in G allele carriers	AG+GG vs AA	3.66	1.54-8.73	0.003
		Kubben[14]	Gastric	Caucasian	79/169	Cancer risk	More AA and less AG in cancer group	AG+GG vs AA	0.50	0.28-0.87	< 0.04
						Tumor-related survival	No difference in tumor-related survival
		Li[64]	Gastric	Chinese	338/380	Cancer risk	Increased cancer risk in G allele carriers	AG+GG vs AA	1.95	1.24-3.05	0.004
						LN metastases	Increased risk of LN metastases in G allele	AG+GG vs AA			0.040
						Cancer stage	More advanced cancer stage in G allele	AG+GG vs AA			0.007
		Alakus[56]	Gastric	Caucasian	135/58	Cancer risk	No difference in cancer risk	AG+GG vs AA	1.06	0.69-1.64	0.79
						Overall survival	No difference in overall survival
		Zhang[45]	GCA	Chinese	201/350	Cancer risk	Increased cancer risk in G allele carriers	AG+GG vs AA	1.96	1.17-3.29
						LN metastases	No difference in LN metastases
MMP-7	-153 C/T	Kubben[14]	Gastric	Caucasian	79/169	Cancer risk	No difference in cancer risk
						Tumor-related survival	No difference in tumor-related survival
MMP-8	17 C/G	Kubben[14]	Gastric	Caucasian	79/169	Cancer risk	No difference in cancer risk
						Tumor-related survival	No difference in tumor-related survival
MMP-9	R279Q	Tang[59]	Gastric	Chinese	74/100	Cancer risk	No difference in cancer risk
						LN metastases	Increased risk of LN metastases in RR	RR vs QQ+RQ	5.74	1.59-13.43
MMP-9	P574R	Tang[59]	Gastric	Chinese	74/100	Cancer risk	No difference in cancer risk
						LN metastases	Increased risk of LN metastases in PP	PP vs RR+PR	4.17	1.39-11.78
MMP-9	-1562 C/T	Kubben[14]	Gastric	Caucasian	79/169	Cancer risk	No difference in cancer risk
						Tumor-related survival	No difference in tumor-related survival
		Matsumura[57]	Gastric	Japanese	177/224	Cancer risk	No difference in cancer risk
						Infiltration depth	Deeper submucosal infiltration in T allele	CT+TT vs CC	2.61	1.07-6.34	0.034
						Lymphatic invasion	Increased lymphatic invasion in T allele	CT+TT vs CC	2.27	1.09-4.74	0.028
						TNM classification	More advanced stage cancer in T allele	CT+TT vs CC	2.26	1.12-4.55	0.022
						Venous invasion	No difference in venous invasion	CT+TT vs CC	1.98	0.99-3.97	0.053
		Zhang[53]	Gastric	Chinese	228/774	Cancer risk	No difference in cancer risk
		Wu[58]	Gastric	Taiwanese	263/354	Cancer risk	No difference in cancer risk
MMP-12	-82 A/G	Li[39]	GCA	Chinese	335/624	Cancer risk	No difference in cancer risk
						Cancer risk in smoker	No difference in cancer risk in smoker
MMP-13	-77 A/G	Li[39]	GCA	Chinese	257/624	Cancer risk	No difference in cancer risk
						Cancer risk in smoker	Decreased cancer risk in AG in smoker	AG vs AA/AG	0.47	0.28-0.8	0.01
		Zhang[41]	GCA	Chinese	243/609	Cancer risk	No difference in cancer risk
						Cancer risk in smoker	Decreased cancer risk in AG in smoker
TIMP-1	372 C/T	Kubben[14]	Gastric	Caucasian	79/169	Cancer risk	No difference in cancer risk
						Tumor-related survival	No difference in tumor-related survival
TIMP-2	-418 G/C	Kubben[14]	Gastric	Caucasian	79/169	Cancer risk	No difference in cancer risk
						Tumor-related survival	No difference in tumor-related survival
		Wu[55]	Gastric	Taiwanese	240/283	Cancer risk	No difference in cancer risk
						LN metastases	Increased risk of LN metastases in GG	GG vs CG+GG	2.87	1.22-6.76	0.16
						Venous invasion	Increased venous invasion in GG	GG vs CG+GG	2.65	1.08-6.49	0.033
						Survival	No difference in survival
		Yang[66]	Gastric	China	206/206	Cancer risk	More C-alleles in cancer patients	CC+CG vs GG	1.51	1.00-2.26	0.049
						Clinicopathol. par.	No correlation with any clinicopath. par.
TIMP-2	303 C/T	Kubben[14]	Gastric	Caucasian	79/169	Cancer risk	No difference in cancer risk
						Tumor-related survival	Better survival in CC patients	CC vs CT/TT	4.45	1.81-10.9	0.001
		Alakus[56]	Gastric	Caucasian	135/58	Cancer risk	No difference in cancer risk
						LN metastases	More LN metastases in CC				0.01
						Distant metastases	Increased risk of distant metastases in CC				0.022
						Survival	No difference in survival

SNP: Single nucleotide polymorphism; GCA: Gastric Cardia Adenocarcinoma; LN: Lymph node; OR: Odds ratio; 95% CI: 95% confidence interval; Clinicopath. par.: Clinicopathological parameters. ¹Except histological subtype.